What is Cofactor Genomics?
Cofactor Genomics is at the forefront of precision oncology, leveraging advanced RNA-Seq technology to develop predictive diagnostics. Their proprietary OncoPrism assay is designed to accurately forecast patient responses to immunotherapy, a critical advancement for matching cancer patients with the most effective treatments. The company's work is validated through ongoing clinical trials across more than 24 healthcare systems. By utilizing multidimensional biomarkers, Cofactor Genomics enhances the understanding of tumor responses, thereby improving the efficacy of personalized cancer care for medical oncologists, pathologists, and clinical researchers.
How much funding has Cofactor Genomics raised?
Cofactor Genomics has raised a total of $21.5M across 5 funding rounds:
Other Financing Round
$2.6M
Other Financing Round
$120K
Series A
$18M
Debt
$350K
Debt
$424K
Other Financing Round (2015): $2.6M with participation from BioGenerator, 7percent Ventures, David Lee, Jude Gomila, Paul Buchheit, TenOneTen, Data Collective, and AME Cloud
Other Financing Round (2015): $120K led by Y Combinator
Series A (2017): $18M supported by Wilson Sonsini Goodrich & Rosati, Menlo Ventures, Ascension Ventures, iSelect Fund Management, Data Collective, Y Combinator, and Stanford
Debt (2020): $350K featuring PPP
Debt (2021): $424K backed by PPP
Key Investors in Cofactor Genomics
Y Combinator
Y Combinator is a renowned accelerator that provides seed funding and mentorship to early-stage startups, known for its significant impact on the tech ecosystem.
Data Collective
Data Collective is a venture capital firm focused on data-intensive technologies, supporting companies that build infrastructure and value chains around data.
Menlo Ventures
Menlo Ventures is a venture capital firm that invests in early and growth-stage technology companies, partnering with founders to scale their businesses.
What's next for Cofactor Genomics?
The recent major strategic investment positions Cofactor Genomics for significant growth and expansion. With a focus on scaling its operations and further validating its diagnostic technologies, the company is poised to deepen its impact on the precision medicine landscape. Future endeavors will likely involve broader clinical integration, strategic partnerships with healthcare providers and pharmaceutical companies, and continued innovation in biomarker discovery to address unmet needs in immune-oncology. This capital will fuel their mission to revolutionize cancer treatment by providing clinicians with actionable insights for patient care.
See full Cofactor Genomics company page
